Low-dose maintenance gemcitabine-carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma

International Journal of Urology

Volumn 21, Issue 11, 2014, Pages 1114-1119

  Mitsuzuka, Koji ^a   Yamashita, Shinichi ^a   Namiki, Shunichi ^a   Yamada, Shigeyuki ^a   Sato, Ko ^a   Saito, Hideo ^a   Kaiho, Yasuhiro ^a   Ito, Akihiro ^a   Nakagawa, Haruo ^a   Arai, Yoichi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adverse event; Carboplatin; Cisplatin unfit; Low dose maintenance chemotherapy; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DEOXYCYTIDINE; GEMCITABINE;

AGED; ANALOGS AND DERIVATIVES; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; UROLOGIC NEOPLASMS;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UROLOGIC NEOPLASMS;

EID: 84937208843     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12532     Document Type: Article

References (23)

1. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J. Urol. 2005; 174: 14-20.
2. Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit. Rev. Oncol. Hematol. 2003; 46 (Suppl): S105-115.
3. von der Maase H, Hansen SW, Roberts JT etal. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 2000; 18: 3068-3077.
4. Dash A, Galsky MD, Vickers AJ etal. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006; 107: 506-513.
5. Bellmunt J, Albanell J, Gallego OS etal. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 1992; 70: 1974-1979.
6. Galsky MD, Hahn NM, Rosenberg J etal. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J. Clin. Oncol. 2011; 29: 2432-2438.
7. Nogue-Aliguer M, Carles J, Arrivi A etal. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 2003; 97: 2180-2186.
8. Scher HI, Yagoda A, Herr HW etal. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors. J. Urol. 1988; 139: 475-477.
9. Eisenhauer EA, Therasse P, Bogaerts J etal. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009; 45: 228-247.
10. De Santis M, Bellmunt J, Mead G etal. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J. Clin. Oncol. 2012; 30: 191-199.
11. Witjes JA, Comperat E, Cowan NC etal. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: summary of the 2013 Guidelines. Eur. Urol. 2014; 65: 778-792.
12. De Santis M, Bellmunt J, Mead G etal. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II-results of EORTC study 30986. J. Clin. Oncol. 2009; 27: 5634-5639.
13. Morales-Barrera R, Bellmunt J, Suarez C etal. Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur. J. Cancer 2012; 48: 1816-1821.
14. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J. Clin. Oncol. 2002; 20: 937-940.
15. Papamichael D, Gallagher CJ, Oliver RT, Johnson PW, Waxman J. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br. J. Cancer 1997; 75: 606-607.
16. McCaffrey JA, Hilton S, Mazumdar M etal. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J. Clin. Oncol. 1997; 15: 1853-1857.
17. Witte RS, Manola J, Burch PA, Kuzel T, Weinshel EL, Loehrer PJ Sr. Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial. Invest. New Drugs 1998; 16: 191-195.
18. Witte RS, Elson P, Bono B etal. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J. Clin. Oncol. 1997; 15: 589-593.
19. Sweeney CJ, Roth BJ, Kabbinavar FF etal. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J. Clin. Oncol. 2006; 24: 3451-3457.
20. Culine S, Theodore C, De Santis M etal. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br. J. Cancer 2006; 94: 1395-1401.
21. Bellmunt J, Theodore C, Demkov T etal. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 2009; 27: 4454-4461.
22. Gentzler RD, Patel JD. Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications. Ther. Adv. Med. Oncol. 2014; 6: 4-15.
23. Dogliotti L, Carteni G, Siena S etal. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur. Urol. 2007; 52: 134-141.